Renal Kidney Replacement Therapies Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 10 Year, 17 Days
- Last Filing with ROC 31 Mar 2021
- Revenue Growth %
- Profit Growth -576.43%
- Ebitda -576.43%
- Net Worth -20.91%
- Total Assets -1.11%
About Renal Kidney Replacement Therapies
Renal Kidney Replacement Therapies Private Limited (RKRTPL) is a Private Limited Indian Non-Government Company incorporated in India on 22 January 2015 and has a history of Ten years. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Hemavathi Pulla and Kamala Pulla serve as directors at the Company.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U85110TG2015PTC097345
-
Company No.
097345
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
22 Jan 2015
-
Date of AGM
30 Nov 2021
-
Date of Balance Sheet
31 Mar 2021
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Renal Kidney Replacement Therapies?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Hemavathi Pulla | Additional Director | 20-Nov-2024 | Current |
| Kamala Pulla | Additional Director | 29-Nov-2024 | Current |
Financial Performance of Renal Kidney Replacement Therapies.
Renal Kidney Replacement Therapies Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 576.43% decrease in profit. The company's net worth observed a substantial decline by a decrease of 20.91%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Renal Kidney Replacement Therapies?
In 2017, Renal Kidney Replacement Therapies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Renal Kidney Replacement Therapies?
Unlock and access historical data on people associated with Renal Kidney Replacement Therapies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Renal Kidney Replacement Therapies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Renal Kidney Replacement Therapies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
